Beijing: The Chinese state media quoted the State Intellectual Property Office on Sunday (16th) that the COVID-19 vaccine “Ad5-nCoV vaccine” jointly developed by the research team led by Chen Wei of the Academy of Military Medical Research and CanSino Biosciences has been granted the first COVID-19 vaccine patent.
The team led by Chen Wei has developed a recombinant COVID-19 vaccine and has taken the lead in entering phase I and phase II clinical trials at home and abroad. The safety and immunogenicity of the vaccine have been verified, and the phase III international clinical trials are proceeding in an orderly manner.
Around 170 different vaccine trials of Corona are underway worldwide. According to a report, about 139 vaccines in the world are in pre-clinical trial phase. At the same time, 25 vaccines are in the first phase of trial. 17 vaccines are in the second phase of the trial. 7 vaccines are in the third phase of the trial. Explain that as soon as the third phase is completed, the vaccine only needs approval and after that the production of the vaccine will start.
